Skip to content
‹ Back to IndustriesSciences

Forging Connections: Flipping CAPA on Its Head with Prevention

Waste and lost money run rampant in various sectors, and healthcare and pharmaceuticals are no exception. Bethany Kearney, Director of Enablement for Sparta Systems, and Zillery Fortner, Product Advisor, QA/RA Life Sciences at Sparta Systems, joined Forging Connections Host Michelle Dawn Mooney to discuss flipping corrective and preventive action (CAPA) on its head through preventive…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Healthcare · · KappaMedical DevicesPharmaceuticalsRecall
Share

Key takeaways

01

Waste and lost money run rampant in various sectors, and healthcare and pharmaceuticals are no exception.

02

Bethany Kearney, Director of Enablement for Sparta Systems, and Zillery Fortner, Product Advisor, QA/RA Life Sciences at Sparta Systems, joined Forging Connections Host Michelle Dawn Mooney to discuss flipping corrective and preventive action (CAPA) on its head through preventive…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Waste and lost money run rampant in various sectors, and healthcare and pharmaceuticals are no exception. Bethany Kearney, Director of Enablement for Sparta Systems, and Zillery Fortner, Product Advisor, QA/RA Life Sciences at Sparta Systems, joined Forging Connections Host Michelle Dawn Mooney to discuss flipping corrective and preventive action (CAPA) on its head through preventive measures.

Fortner provided an example of how reusable medical devices like gowns would rip after 40 uses or so when they were supposed to last for 100 lifecycles. The safety complaints stopped at a high level instead of digging down deep to find the root cause. Issues were accredited to “human error” or incorrect repair. “There wasn’t global communication between the different facilities. There were multiple issues going on. Multiple times it was closed in CAPA, saying it was fixed. When it came down to it, the true root cause was a chemical reaction,” Fortner stated. Addressing the actual cause would have saved millions of dollars.

“Finding the true root cause is very complex. It’s easy to blame a human, and if the firm is 100 percent focused on metrics, then finding the true root cause is going to be very challenging. Because in some cases, it is costly,” Kearney explained. She added, “It’s much more costly to not know that true root cause,” and that “putting in the time to do it right is really where the value is.”

The key is to follow the seven steps of the CAPA process. Fortner listed them as identifying the problem, evaluating the problem, developing and investigating, analyzing the problem, creating an action plan, implementing it, and analyzing the effectiveness.

Fortner added that prevention is essential, and companies should plan, do, check, act…Lacking support from the right stakeholders will cause you to struggle and make the process difficult. It is also imperative not to play the blame game and to understand why the mistake happened, fix it, and ensure the fix works.

When CAPAs go awry, this can cause incredibly costly issues. “A recall is just one part of doing something wrong or not really, truly understanding the problem,” stated Fortner. “A recall process can cost up to 600 million dollars, according to research from McKinsey. The medical device industry spends around 5 billion dollars a year on recalls. This expense we can’t ignore because lives are at risk. Every minute that a defective product stays out on the market is another opportunity for someone to be injured.”

“The payoff to doing CAPA right, I don’t think you can measure,” stated Fortner.

For more podcasts from Forging Connections, visit Apple iTunes or Spotify.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel and Warwick have developed a version of two-dimensional mass spectrometry called Q-2DMS. Until now, only the best-funded centers could afford 2DMS hardware, and Verdel's chief executive argues that the field lacked access, not an understanding of what the method can do. If 2DMS moves onto more common hardware, more labs could evaluate it. Published results show up to tenfold more usable spectral information on closely related or near-isobaric compounds, the look-alike molecules that separation and filtering tend to blur together or drop.

  • 01The reported gain of up to tenfold more usable spectral information applies to closely related or near-isobaric compounds, so the best trial samples are the mixtures chromatography struggles to separate.
  • 02A complete time-stamped record can be revisited after a sample runs out or degrades, and a full acquisition could, in principle, let archived runs address new questions later.

Oct 9, 2026

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512